Access can feel stable until it is not. For a period of time, a product may be available, pricing may feel predictable, and the process may become familiar. People start to believe the path they are using will remain open because it has been open for months. Then the market changes.
The molecule name may look familiar. The science may look familiar. But the regulatory access pathway can change.
That is what makes shortages so disruptive.
THE ACCESS WINDOW
Shortages can temporarily reshape the market. When an FDA-approved drug is on FDA's drug shortages list, certain compounding pathways may become available under specific legal conditions. That does not mean the compounded drug has been FDA approved or reviewed before marketing for safety, effectiveness, and quality. It means FDA shortage status can create a temporary environment where certain forms of compounding may be permitted if the compounder meets applicable requirements.
That distinction matters. FDA's April 1, 2026 update says semaglutide and tirzepatide do not currently appear on FDA's drug shortage list.
The access exists because the system is under pressure. When the shortage changes, the access structure can change with it.
THE SHIFT
This is why access can feel like it changes overnight. During a shortage, more sources may appear. More pricing options may exist. The market may feel more flexible. People may assume that flexibility is permanent because it becomes part of their routine.
But shortage-based access is not designed to be permanent.
When supply stabilizes and FDA determines that a shortage has been resolved, compounders may be required to stop making products that are essentially copies of FDA-approved drugs, subject to 503A and 503B rules, existing-order limits, and enforcement timelines. In FDA's February 21, 2025 semaglutide injection shortage resolution, the agency described enforcement-discretion periods until April 22, 2025 for certain 503A compounders and until May 22, 2025 for 503B outsourcing facilities.
From the outside, that can feel sudden. A source that was available one month may no longer be available the next. Prices can shift as options contract. People who built their routine around one access pathway may have to start evaluating alternatives.
THE CONFUSION
The confusing part is that the molecule remains recognizable while the system around it changes. This is where many people feel caught off guard. They are not reacting to a change in the science. They are reacting to a change in the legal, supply, and distribution environment around that science.
That is why access is not just a product issue. It is a system issue.
A familiar molecule name can move through different access pathways depending on FDA shortage-list status, regulatory position, supply conditions, and distribution model. That does not make the products equivalent. It means the pathway around the product can change, and the person at the end of the chain feels the impact.
What this means
Shortages teach one important lesson: access is not guaranteed just because demand exists.
A source may be available because of a temporary condition. A price may exist because of a temporary market structure. A familiar pathway may depend on rules that can change once supply stabilizes.
The useful question is not only: can I access this today? The better question is: what system is making this access possible, and how stable is that system?
In this market, a familiar molecule name can sit inside a changing access pathway. That is why understanding the regulatory system matters.
In this market, access can change when FDA shortage-list status and regulatory pathways change.